Sinopharm approved the first "vaccine export"

Source: if there is no accident on October 22, 2013, China's first vaccine with "export right" will be listed in the United Nations vaccine procurement list at the GAVI meeting one month later The vaccine manufacturer, Sinopharm, will therefore open the UN Procurement channel, and will also open the door to the global valuable vaccine market because of the "international green card" for vaccine export China's first vaccine "green card" yesterday, Sinopharm held a small communication meeting, announcing that its affordable vaccine for children's encephalitis B officially obtained the pre certification of the World Health Organization (who) Its subordinate Chengdu Institute of biological products (hereinafter referred to as "Chengdu Institute") immediately became the first Chinese vaccine company to obtain the pre certification of who "According to the normal process, at the global alliance for vaccine and immunization meeting in November, children's JE vaccine born in Sinopharm will be discussed and listed in the 2014 UN vaccine procurement list, with a conservative estimated procurement volume of more than 10 million people." Zhang Jiankang, a Chinese representative of the international non-profit organization pass for health (hereinafter referred to as "pass"), said in an interview As an international non-profit organization, pass has provided economic and technical support for the vaccine project of Sinopharm At the same time, it is also funded by the Gates Foundation According to the public information, who pre certification is the most critical link for vaccines to enter the United Nations procurement catalogue, and at the same time provides quality reference to other countries using vaccines In other words, after passing the WHO pre certification, the vaccine can not only be used within the scope of United Nations procurement, but also be sold to a wider range of other countries around the world, which can be described as "both fame and wealth" According to relevant information provided by pass, there are more than 4 billion people living in Southeast Asia and the Western Pacific region where JE is prevalent This disease, which is mainly transmitted by mosquitoes, causes 70000 cases of infection every year, with a mortality rate of 21.4%, which is the primary cause of viral neurological diseases and disability in Asia "What's more terrible is that even the data we have now may be far lower than the real situation and underestimate the real harm of the disease because of the complexity and lack of systematic monitoring of the diagnosis of the disease for a long time." Zhang Jiankang told reporters The opportunity for Sinopharm is that before it, there has not been any vaccine for children's JE in the United Nations vaccine procurement list This huge gap needs to be filled urgently It is understood that the price of the vaccine in Chengdu Branch of Zhongsheng Co., Ltd is far lower than the current similar vaccine in India "Take the JE vaccine as an example We signed a 20-year supply agreement with Sinopharm Chengdu to ensure the price stability and continuous supply of the vaccine." Zhang Jiankang told this newspaper, "according to the international pricing principle, the vaccine pricing is based on its cost accounting plus 15% - 30% of the normal profit If the cost of that year has increased, it will make corresponding adjustments, but the purpose is to ensure a stable supply of vaccines." For Sinopharm, one of the world's largest vaccine manufacturers, UN Procurement is clearly the first step in its global layout "Pass's support and who's pre certification give us the honor to bring China to the global vaccine stage" - referring to this breakthrough, Yang Xiaoming, President and CEO of Sinopharm, spoke highly of his ambition to enter the international market According to the information from PAS, at present, beyond the access to the United Nations procurement channel, Sinogen Japanese encephalitis vaccine has successively entered the public markets of 11 countries, such as Russia and Vietnam, with sales exceeding 200 million According to the industry division, "public market" refers to the planned vaccine purchased by the government or institutions The market outside this scope is generally defined as "private market" Because of the different pricing principles, the vaccine price is generally higher, which is commonly known as "valuable vaccine" According to the current situation in China, there are 36 vaccine manufacturers, which can produce 27 kinds of vaccines to prevent 27 diseases, with an annual production supply of 1 billion doses, because the national "12th Five Year Plan" and other key supporting policies all focus on the development of biomedicine and provide 40 billion yuan of special funds for the research, development and innovation of biomedicine While domestic enterprises are actively increasing their investment in vaccine field, International Vaccine giants are also stepping up their investment in Chinese market In 2013, four new Chinese factories of French vaccine giant Sanofi will be put into production one after another, the most important of which is the influenza vaccine factory in Shenzhen The annual production capacity of the vaccine factory will reach 25 million doses, which is also the first Chinese vaccine factory established by a multinational pharmaceutical company in China The vaccine cooperation between MSD, the fifth largest pharmaceutical company in the world, and Zhifei biology, the leading private vaccine company in China, has entered its fourth year In July 2010, MSD and Sinopharm signed a memorandum of strategic cooperation, and both sides publicly expressed their hope to further discuss the establishment of a joint venture and cooperation in the field of HPV vaccine; in 2011, as 15 In the first part of the $100 million dialogue investment, MSD announced the establishment of its Asian R & D headquarters in Beijing Vaccine R & D is one of the most important research directions "The cooperation between the two sides has indeed been affected by the listing of Sinopharm in Hong Kong stock market, and a lot of work has been suspended." Yesterday, when it came to this matter, a person close to Sinopharm told reporters, "with the export license of who granted to Sinopharm this time, cooperation between the two sides may produce more variables." He believes that although Sinopharm seems to only enter the public market purchased by the United Nations this time, because it has obtained who quality certification, it has been unstoppable to open up the international market for valuable vaccines - "before its launch, its positioning for the international market and the domestic market is likely to be reconsidered."